Article information
Full text is only aviable in PDF
Bibliografía
[1.]
M. Chang-Yeung, N.L. Müller.
Cryptogenic fibrosing alveolitis.
Lancet, 350 (1997), pp. 651-656
[2.]
R.M. du Bois.
Diffuse lung disease: an approach to management.
Br Med J., 309 (1994), pp. 175-179
[3.]
G.W. Hunninghake, A.R. Kalica.
Approaches to the treatment of pulmonary fibrosis.
Am J Respir Crit Care Med, (1995), pp. 915-918
[4.]
I.D.A. Johnston, S.A. Gomm, S. Kalra, J.A. Woodcock, C.C. Evans, C.R. Hind.
The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom.
Eur Respir J, 6 (1993), pp. 891-893
[5.]
D.B. Coultas, R.E. Zumwalt, W.C. Black, R.E. Sobonya.
The epidemiology of interstitial lung diseases.
Am J Respir Crit Care Med, 150 (1994), pp. 967-972
[6.]
D.W. Mapel, J.M. Samet, D.B. Coultas.
Corticosteroids and the treatment of idiopathic pulmonary fibrosis.
Chest, 110 (1996), pp. 1.058-1.067
[7.]
J.P. Lynch, W.J. Mc Cune.
Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders.
Am J Respir Crit Care Med, 155 (1997), pp. 395-420
[8.]
G. Raghu, W.J. Depasso, K. Cain, S.P. Hammar, C.E. Wetzel, D.F. Dreis, et al.
Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled clinical trial.
Am Rev Respir Dis, 144 (1991), pp. 291-296
[9.]
M.A. Johnson, S. Kwan, N.J. Snell, A.J. Nunn, J.H. Darbyshire, M. Turner-Warwick.
Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisone in combination in cryptogenic fibrosing alveolitis.
Thorax, 44 (1989), pp. 280-288
[10.]
K.B. Van Oortegem, B. Wallaert, C.H. Marquette, P. Ramon.
Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis.
Eur Respir J, 7 (1994), pp. 1.950-1.957
[11.]
R.P. Baughman, E.E. Lower.
Use of intermitent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis.
Chest, (1992), pp. 1.090-1.094
[12.]
E.W. Alton, M. Johnson, M. Turner Warwick.
Advanced cryptogenic fibrosing alveolitis: preliminaryy report on treatment with cyclosporin A.
Respir Med, 83 (1989), pp. 277-279
[13.]
J.A. Moolman, P.G. Bardin, D.J. Rossouw, J.R. Joubert.
Cyclosporin as a treatment for interstitial lung disease of unknown etiology.
Thorax, 46 (1991), pp. 592-595
[14.]
C. Agustí, A. Xaubet, E. Ballestser, J. Prieto, A. Alarcón, C. Picado.
Aerosolized ribavirin in patients with advanced cryptogenic fibrosis alveolitis.
A pilot study. Thorax, 48 (1993), pp. 68-69
[15.]
G. Raghu.
Idiopathic pulmonary fibrosis: a need for treatment with drugs other than corticosteroids. A role for antibrotic agents?.
Mayo Clin Proc, 72 (1997), pp. 285-287
[16.]
W.W. Douglas, J.H. Ryu, J.A. Bjoraker, D.R. Schroeder, J.L. Myers, H.D. Tazalaar, et al.
Colchicine versus prednisone as treatment of usual interstitial pneumonia.
Mayo Clin Proc, 72 (1997), pp. 201-209
[17.]
A.S. Narayanan, J. Whithey, A. Souza, G. Raghu.
Effect of interferon-γ on collagen synthesis by normal and fibrotic lung fibroblasts.
Chest, 101 (1992), pp. 1.326-1.331
[18.]
S.N. Iyer, J.S. Wild, M.J. Schiedt, D.M. Hyde, S.B. Margolin, S.N. Giri.
Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.
J Lab Clin Med, 125 (1995), pp. 779-785
[19.]
I.D.A. Johnston, R.J. Prescott, J.C. Chalmers, R.M. Rudd.
British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management.
Thorax, 52 (1997), pp. 38-44
[20.]
J. Wilson, C. Dayton, J. Galvin, P. Hartley, G. McLennan, S. Yagla.
Longitudinal stability in a subset of patients with idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 153 (1996),
[21.]
C. Agustí, A. Xaubet, A.G.N. Agustí, J. Roca, J. Ramírez, R. Rodríguez-Roisin.
Clinical assessment of patients with idiopathic pulmonary fibrosis: results of a three years follow-up.
Eur Respir J, 7 (1994), pp. 643-650
[22.]
C.B. Carrington, E.A. Gaensler, R.E. Coutu, M.X. Fitzgerald, R.G. Gupta.
Natural history and treated course of usual and dequamative interstitial pneumonia.
N Engl J Med, 298 (1978), pp. 801-809
[23.]
S.E. Gay, E.A. Kazerooni, G.B. Toews, J.P. Lynch, B.H. Gross, P.N. Cascade, et al.
Idiopathic pulmonary fibrosis. Predicting response to therapy and survival.
Am J Respir Crit Care Med, 157 (1998), pp. 1.063-1.072
[24.]
J.A. Bjoraker, J.H. Ryu, M.K. Edwin, J.L. Myers, H.D. Tazelaar, D.R. Schroeder, et al.
Prognostic significance of histiopathologic subsets in idiopathic fibrosis.
Am J Respir Crit Care Med, 157 (1998), pp. 100-203
[25.]
A.L.A. Katzenstein, J.L. Myers.
Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification.
Am J Respir Crit Care Med, 157 (1998), pp. 1.301-1.315
[26.]
C. Agustí, P. Luburich.
¿Qué aporta la TAC de alta resolución en el estudio de las enfermedades intersticiales difusas?.
Arch Bronconeumol, 31 (1995), pp. 311-313
[27.]
A.U. Wells, M.B. Rubens, R.M. du Bois, D.M. Hansell.
Serial CT in the fibrosing alveolitis: prognostic significance of the initial pattern.
Am J Roentgenol, 161 (1993), pp. 1.159-1.165
[28.]
A. Xaubet, C. Agustí, P. Luburich, J.A. Barberá, C. Montón, M.C. Ayuso, et al.
Pulmonary function tests and CT scans in the management of idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med, 158 (1998), pp. 431-436
[29.]
J.M. Borro, P. Morales, C. Lozano, V. Tarazona, G. Galán, V. Calvo, et al.
1990-1996: experiencia del Grupo de Trasplante Pulmonar de la Fe (Valencia).
Arch Bronconeumol, 33 (1997), pp. 438-443
[30.]
F. Morell, A. Román, C. Bravo, F. Nicolau, S. Martí.
Resultados de la evaluación de los 208 pacientes remitidos en los primeros 4 años a un programa de trasplante pulmonar.
Arch Bronconeumol, 32 (1996), pp. 280-284
[31.]
M.T. Lázaro-Carrasco, P. Ussetti, M.J. Ferreiro, N.C. Carreño, A. Pablo, F. García, et al.
Análisis de la supervivencia del trasplante pulmonar en la Clínica Puerto de Hierro.
Arch Bronconeumol, 34 (1998), pp. 285-288
Copyright © 1998. Sociedad Española de Neumología y Cirugía Torácica
